A biotechnology Start-up born at Tohoku University.
Pioneering new frontiers in protein engineering through the fusion of AI and directed evolution.

Mission & Values

Mission

Our mission is to contribute to the health and well-being of people around the world by growing,evolving, and providing life-saving biopharmaceuticals using RevolKa’s innovative AI technology.

Value

Our Three Core Values

  • Growth and
    Evolution
  • Takumi
    (Artisanship)
  • Explore and
    Innovate

Message

Lead the Evolution

RevolKa is an enthusiast of proteins, which are highly functional molecules in biological reactions.
During the evolution of life, proteins have been transformed in response to environmental changes.
This flexible adaptation has created the current diversity of proteins and organisms.

In the last decades, proteins, especially antibodies are developed as therapeutic molecules and have become one of the major modalities in biopharmaceuticals.
Enzymes are also utilized as efficient biocatalysts in industries. Despite these growing utilizations, the relationship between amino acid sequence, three-dimensional structure, and function still remains to be elucidated for the rational protein design.

We integrated directed protein evolution with artificial intelligence to create a proprietary protein engineering technology, called aiProtein®.
Leveraging this own technology, RevolKa is passionate about the creation of innovative proteins.

RevolKa Ltd.
President and CEO Norio Hamamatsu, Ph.D.

Company Profile

Company Revolka Ltd.
Head Office Aoba-ku, Sendai
Establish Date April, 2021
Capital 100 million yen (As of January 31th, 2026)
Business Category
  • Development of highly functional proteins using AI
  • Drug discovery
  • Contract research and development
  • Joint research and development
Number of Employees 25(including officers and temporary employees)
Member Organizations
  • The Antibody Society of Japan
  • Japan Bioindustry Association
  • Sendai Chamber of Commerce and Industry

Our History

2021

  1. April

    Established RevolKa Ltd. in Chuo-ku, Tokyo as a venture from Tohoku University

  2. June

    Concluded a joint research agreement with Tohoku University

  3. June

    Completed the first seed round of funding（60 million yen）

2022

  1. January

    Opened Sendai Laboratory in Aoba-ku, Sendai

  2. January

    Completed the second seed round of funding（60 million yen）

  3. March

    Concluded a joint research agreement with Sumitomo Dainippon Pharma Co., Ltd. (now Sumitomo Pharma Co., Ltd.)

  4. April

    Opened Tokyo Laboratory in Chuo-ku, Tokyo

  5. May

    Completed Series A round of funding（350 million yen）

  6. September

    Opened US office in Cambridge, Massachusetts, USA

  7. October

    Concluded a joint research agreement with Tokyo Medical and Dental University

  8. November

    Moved Tokyo Laboratory to Bunkyo-ku, Tokyo

2023

  1. July

    Moved Head office to Bunkyo-ku, Tokyo

  2. September

    Closed Tokyo Laboratory

2024

  1. January

    Completed Series A extension round of funding（150 million yen）

  2. August

    Completed Series A extension round of additional funding（100 million yen）

2025

  1. February

    Moved Head office to Aoba-ku, Sendai

  2. May&July

    Completed Series A extension round of additional funding（230 million yen）

  3. September

    Launched ‘RevoAb™’

  4. December

    Moved Tokyo office to Minato-ku, Tokyo

Co-founder

Shiro Kataoka, Ph.D.

Mitsuo Umetsu, Ph.D.

Hikaru Nakazawa, Ph.D.

Management

President and CEO

Norio Hamamatsu, Ph.D.

Board Director and CSO

Mitsuo Umetsu, Ph.D.

Board Director

Ayumi Iwase

Outside Board Director

Fumihiro Nakamori, Ph.D.

Outside Board Director

Kenji Watatani, Ph.D.

Corporate Auditor

Naoya Onaka

Adviser

Scientific Advisor

Kouji Tsuda, Ph.D.

Scientific Advisor

Hahumi Nishi, Ph.D.

Scientific Advisor

Yutaka Saito, Ph.D.

Technical Advisor

Hikaru Nakazawa, Ph.D.

Strategy Advisor

Masanori Sato

Medical Advisor

Akihiro Kume, M.D., Ph.D.

Medical Advisor

Toshihiro Ohura, M.D., Ph.D.

Access

  • RevolKa head office・Sendai Laboratory

    Address
    208・301・309 T-Biz, 6-6-40, Aoba, Aramaki, Aoba-ku, Sendai 980-0845, Japan
    Google Map
    Access
    About 2-minutes walk from the North Exit of “Aobayama Station” on Sendai Subway Tozai Line

  • RevolKa Tokyo office

    Address
    7F Shin-Aoyama Building East Building, 1-1-1 Minami-Aoyama, Minato-ku, Tokyo 107-0062, Japan
    Google Map
    Access
    Directly connected to Aoyama-itchome Station on the Tokyo Metro Ginza Line, Hanzomon Line, and Toei Oedo Line

  • RevolKa U.S. Office

    Address
    One Broadway, Cambridge, MA 02142, USA
    Google Map